|
Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). |
| |
|
Honoraria - Advanced Accelerator Applications/Imaging Equipment Ltd; Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daichi-Sankyo; Incyte; Ipsen; Janssen; Lilly; MSD; Pierre Fabre; Roche; Sanofi; Sirtex Medical; TERUMO; TERUMO |
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Daichi-Sankyo; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche; Sirtex Medical; Terumo |
Research Funding - Novartis |
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Roche |
| |
|
Honoraria - Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; SynCoreBio; TTY Biopharm |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CStone Pharmaceuticals; Ipsen; Lilly; MSD; Ono Pharmaceutical; Onward Therapeutics; Taivex Therapeutics |
Research Funding - ACT Genomics; Celgene; Ministry of Health and Welfare Taiwan; Ministry of Science and Technology, Taiwan; Novartis; OBI Pharma; Pfizer; Polaris; SynCoreBio; TTY Biopharm |
Patents, Royalties, Other Intellectual Property - HunilifeTaiwan |
| |
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Eisai |
Research Funding - Genentech; Merck |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
Mairead Geraldine McNamara |
Honoraria - Advanced Accelerator Applications (Inst); Novartis |
Consulting or Advisory Role - AstraZeneca (Inst); Incyte; Ipsen; Shire; Sirtex Medical |
Speakers' Bureau - Nucana |
Research Funding - Ipsen; Nucana; SERVIER |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Novartis |
| |
|
Research Funding - AstraZeneca (Inst); Delta-Fly Pharma (Inst); IQvia (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
| |
|
|
Travel, Accommodations, Expenses - AstraZeneca |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Zymeworks |
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER |